TrialJAMA network open2024

Ramucirumab, Avelumab, and Paclitaxel as Second-Line Treatment in Esophagogastric Adenocarcinoma: The Phase 2 RAP (AIO-STO-0218) Nonrandomized Controlled Trial.

Peter Thuss-Patience et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.